[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 276,915
  • Shares Outstanding, K 83,408
  • Annual Sales, $ 13,860 K
  • Annual Income, $ -79,620 K
  • EBIT $ -83 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.31
  • Price/Sales 20.10
  • Price/Cash Flow N/A
  • Price/Book 16.97

Options Overview Details

View History
  • Implied Volatility 153.62% (+0.90%)
  • Historical Volatility 138.96%
  • IV Percentile 26%
  • IV Rank 12.02%
  • IV High 907.78% on 01/20/26
  • IV Low 50.57% on 09/12/25
  • Expected Move (DTE 21) 0.77 (23.25%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 314
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 7,116
  • Open Int (30-Day) 7,454
  • Expected Range 2.53 to 4.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.27
  • Number of Estimates 4
  • High Estimate $-0.25
  • Low Estimate $-0.31
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +22.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +73.16%
on 08/11/26
4.00 -17.75%
on 08/11/26
+0.38 (+13.06%)
since 07/28/26
3-Month
1.54 +113.64%
on 06/11/26
4.00 -17.75%
on 08/11/26
+1.51 (+84.83%)
since 05/28/26
52-Week
1.03 +219.42%
on 12/26/25
5.55 -40.72%
on 11/26/25
+1.96 (+147.37%)
since 08/28/25

Most Recent Stories

More News
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for...

PYXS : 3.28 (-1.20%)
Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for...

PYXS : 3.28 (-1.20%)
Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment...

PYXS : 3.28 (-1.20%)
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for...

PYXS : 3.28 (-1.20%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 3.52
2nd Resistance Point 3.45
1st Resistance Point 3.38
Last Price 3.28
1st Support Level 3.24
2nd Support Level 3.17
3rd Support Level 3.10

See More

52-Week High 5.55
Fibonacci 61.8% 3.82
Fibonacci 50% 3.29
Last Price 3.28
Fibonacci 38.2% 2.76
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.